
Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis
Keywords: Hepatitis C virus; Gerontology; Cirrhosis; Sofosbuvir; Ribavirin; DAA; HCV; hepatitis C virus; PEG-IFNα; pegylated interferon alpha; DAA; direct-acting antiviral; ITPA; inosine triphosphate pyrophosphatase; eGFR; estimated glomerular filtration rate; IL2